HSP70 is a protein your cells produce to protect themselves from stress. Short for “heat shock protein 70” (named for its 70-kilodalton molecular weight), it belongs to a family of molecular chaperones, proteins whose job is to help other proteins fold into the correct shape and prevent them from clumping together. Your cells make some HSP70 at baseline, but production ramps up dramatically when cells are exposed to heat, infection, toxins, or other forms of damage.
HSP70 is one of the most studied proteins in biology, and for good reason. It plays a central role in keeping cells alive under stress, influences how your immune system responds to threats, and has direct relevance to aging, cancer, and neurodegenerative diseases like Alzheimer’s.
How HSP70 Works Inside Your Cells
Think of HSP70 as a quality-control worker on a factory floor. Proteins in your cells need to fold into precise three-dimensional shapes to function. When a cell is stressed, proteins can misfold or partially unfold, exposing sticky regions that cause them to clump together. HSP70 grabs onto these exposed regions before clumping happens, holds the protein in place, and gives it a chance to refold correctly.
Structurally, HSP70 has two main parts connected by a short flexible linker. The first is a section that binds and breaks down ATP, the cell’s energy currency. The second is the section that physically grabs onto damaged or unfolded proteins. This grabbing section has a base that cradles the target protein and a lid that clamps down to hold it in place. The binding pocket specifically recognizes hydrophobic (water-repelling) stretches of amino acids, which are normally buried inside a properly folded protein but become exposed when that protein unfolds.
The whole process runs on an energy-driven cycle. When ATP binds to the first section, the lid opens and the protein-grabbing section loosens its grip. This lets a misfolded protein slide in. Then the ATP is broken down into ADP, the lid snaps shut, and HSP70 holds its client tightly. Once the ADP is released and a fresh ATP molecule takes its place, the lid opens again, releasing the client protein. If the protein has refolded correctly, it goes on its way. If not, it can be grabbed again for another attempt, or flagged for disposal.
What Triggers HSP70 Production
Your cells always produce a baseline amount of HSP70, but certain stressors cause production to spike. The classic trigger is heat, which is how the protein got its name. Researchers in the 1960s first discovered it by exposing fruit fly cells to elevated temperatures and noticing a burst of new protein production.
In humans, the temperature needed to trigger HSP70 varies by cell type. Immune cells called monocytes are especially sensitive: raising their temperature to just 39°C (about 102°F) for two hours produces a six-fold increase in HSP70 levels, and at 41°C (106°F), levels reach ten times normal. Other white blood cells are less responsive. Certain immune cells called lymphocytes show almost no increase until temperatures hit 42°C (about 108°F), at which point their HSP70 levels jump by 500%.
These findings also apply to whole-body heat exposure. When healthy volunteers sat in a 39.5°C hot water bath for two hours (raising their core temperature to about 39°C), their monocytes showed a 30% increase in HSP70 within three hours, rising to 60% by the next day. This is part of why researchers are interested in practices like sauna bathing, which involves passive exposure to temperatures ranging from 45°C to 100°C depending on the type of sauna.
Beyond heat, HSP70 production also increases in response to infection, inflammation, exposure to heavy metals, low oxygen conditions, and even intense exercise.
HSP70 and Cell Survival
One of HSP70’s most important roles is preventing cells from self-destructing. Cells have a built-in suicide program called apoptosis that activates when damage becomes severe. HSP70 puts the brakes on this process through at least two distinct mechanisms.
First, it blocks a key step in the molecular chain reaction that triggers cell death. Normally, when a cell decides to die, a structure called the apoptosome assembles inside the cell and activates enzymes called caspases that dismantle the cell from the inside. HSP70 prevents the apoptosome from recruiting and activating these enzymes, essentially jamming the self-destruct machinery before it can get going.
Second, HSP70 stabilizes the membranes of lysosomes, small compartments inside the cell that contain digestive enzymes. If lysosomal membranes break, those enzymes leak out and accelerate cell death. HSP70 also helps regulate calcium levels inside the cell. When HSP70 levels drop, intracellular calcium rises, which in turn activates the same destructive enzymes.
Its Role in Neurodegenerative Disease
Many neurodegenerative diseases share a common feature: proteins misfold and clump together into toxic aggregates inside brain cells. In Alzheimer’s disease, the protein tau forms tangled clumps. In Parkinson’s and Huntington’s disease, other proteins aggregate in similar ways. HSP70 directly counteracts this process.
In laboratory studies, HSP70 potently inhibits tau aggregation, preventing both the formation of mature tangles and the smaller intermediate clumps called oligomeric species. The mechanism is specific: HSP70 preferentially binds to soluble, individual tau molecules and small early-stage clumps rather than large, already-formed tangles. By latching onto these early forms, it prevents additional tau molecules from being incorporated into growing aggregates.
This is particularly significant because oligomeric aggregates (the small, early-stage clumps) are increasingly believed to be the most toxic form of tau, doing more damage to neurons than the large fibrillar tangles that have traditionally been the focus of Alzheimer’s research. HSP70’s preference for binding these oligomers suggests it targets the most harmful stage of the aggregation process.
HSP70 Outside the Cell: Immune Signaling
For decades, scientists thought HSP70 only worked inside cells. It turns out that stressed or dying cells release HSP70 into the surrounding tissue, where it takes on a completely different role: acting as a danger signal for the immune system.
Extracellular HSP70 binds to receptors on immune cells called TLR2 and TLR4, the same receptors that detect bacterial invaders. This binding triggers a rapid immune response. In monocytes, it activates a signaling cascade that switches on genes for inflammatory molecules, essentially telling the immune system that nearby cells are in trouble. HSP70 can also promote the maturation of dendritic cells (specialized cells that train the immune system to recognize threats) and activate macrophages that produce reactive oxygen species to kill pathogens.
This dual identity, protective chaperone inside the cell and alarm signal outside it, makes HSP70 a bridge between cellular stress and immune activation.
The Cancer Paradox
HSP70’s ability to keep cells alive is beneficial in healthy tissue but becomes a liability in cancer. Many types of cancer cells overexpress HSP70, essentially hijacking the protein’s anti-death functions to survive conditions that would normally trigger their destruction. High HSP70 levels have been linked to worse outcomes in breast cancer, non-small-cell lung cancer, prostate cancer, gastric cancer, hepatocellular carcinoma, pancreatic cancer, and leukemia.
A meta-analysis of nine studies covering 1,917 colorectal cancer patients found that HSP70 overexpression was associated with poorer overall survival and worse disease-free survival. The protein helps cancer cells resist the very mechanisms, like apoptosis, that the body uses to eliminate them, and that chemotherapy and radiation try to activate.
This has made HSP70 an attractive target for cancer therapy. Researchers are working on inhibitors that would block HSP70’s protective functions specifically in tumor cells, stripping away one of cancer’s key survival tools. These efforts are still largely in preclinical and early clinical stages.
HSP70 Levels Decline With Age
Your body’s ability to produce HSP70 changes over your lifetime, and the pattern is not a simple straight line. Serum HSP70 levels rise during youth and peak between ages 25 and 30. After 30, levels begin to decline. By middle age, the drop becomes significant: in a study of a healthy Chinese population, HSP70 levels in lymphocytes showed a clear negative correlation with age in people over 40, with a steady decline continuing through the late 70s. This decline was consistent regardless of sex.
This age-related decrease is thought to be one reason older adults are more vulnerable to cellular stress. With less HSP70 available, aging cells are less equipped to refold damaged proteins, clear toxic aggregates, and resist apoptosis. The decline in HSP70 production may contribute to the increased susceptibility to neurodegenerative disease, reduced stress tolerance, and impaired immune function that characterize aging. Strategies that boost HSP70 production, whether through heat exposure, exercise, or other stressors, are an active area of interest in longevity research.